Note 13 - Segment Information (Tables)

6 Months Ended

Dec. 31, 2021

Notes Tables

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Quarter Ended						Six Months Ended
	December 31,						December 31,
	2021			2020			2021			2020
Net sales:
Protein Sciences	$	204,971		$	172,179		$	402,156		$	326,625
Diagnostics and Genomics		64,527			52,469			125,512			102,595
Intersegment		(222	)		(395	)		(673	)		(768	)
Consolidated net sales	$	269,276		$	224,253		$	526,995		$	428,452
Operating income:
Protein Sciences	$	93,281		$	80,453		$	183,381		$	150,803
Diagnostics and Genomics		10,880			8,107			18,344			16,781
Segment operating income	$	104,161		$	88,560		$	201,725		$	167,584
Costs recognized on sale of acquired inventory		(84	)		(23	)		(1,595	)		(23	)
Amortization of acquisition related intangible assets		(18,380	)		(15,027	)		(36,769	)		(30,528	)
Impact of partially owned consolidated subsidiaries(1)		(1,004	)		(207	)		(2,567	)		(207	)
Acquisition related expenses		13,262			(4,421	)		15,618			(4,558	)
Eminence impairment		(18,715	)		-			(18,715	)		-
Stock based compensation, inclusive of employer taxes		(14,815	)		(16,225	)		(28,675	)		(29,557	)
Restructuring costs		(743	)		(142	)		(1,928	)		(142	)
Corporate general, selling, and administrative expenses		(1,334	)		(1,520	)		(1,524	)		(2,482	)
Consolidated operating income	$	62,348		$	50,995		$	125,570		$	100,087